First AD

Second AD

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Oncology Nursing News

The OncLive Nursing News condition center page is a comprehensive resource for clinical news and expert insights for oncology nurses and their best practices for treating patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research across malignancies that can be beneficial for oncology nurses.

Supportive Care

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

Recent Advances in Treatment of Acute Myeloid Leukemia

Peer Exchange

QUAZAR: Oral Azacitidine Maintenance in AML

Molecular Testing for AML

AML Induction Strategy and Molecular Testing

Assessment of Fitness for AML Induction Chemotherapy

Decision Making on Consolidation Therapy for AML

Hypomethylating Agents for AML

Venetoclax-Based Regimens for Unfit Patients with AML

Managing Venetoclax-Associated Toxicity in AML

Venetoclax-Based Chemotherapy Combinations in AML

CPX-351 for Secondary AML

Previously Untreated FLT3-Mutated AML

Second-Generation FLT3 Inhibitors for AML

Relapsed/Refractory FLT3-Mutated AML

IDH1/2 Inhibitors in AML

Differentiation Syndrome and IDH1/2 Inhibitors

Gemtuzumab Ozogamicin for CD33+ AML and APL

Immune Checkpoint Inhibitors for AML

Novel Agents Under Investigation for AML